company background image
MEDI

Medistim OB:MEDI Stock Report

Last Price

kr254.00

Market Cap

kr4.6b

7D

-14.0%

1Y

-9.4%

Updated

24 Jun, 2022

Data

Company Financials +
MEDI fundamental analysis
Snowflake Score
Valuation1/6
Future Growth4/6
Past Performance6/6
Financial Health6/6
Dividends3/6

MEDI Stock Overview

Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally.

Medistim Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Medistim
Historical stock prices
Current Share Pricekr254.00
52 Week Highkr409.00
52 Week Lowkr213.50
Beta0.73
1 Month Change0.59%
3 Month Change13.14%
1 Year Change-9.45%
3 Year Change92.42%
5 Year Change217.50%
Change since IPO2,366.02%

Recent News & Updates

Jun 14
A Look At The Intrinsic Value Of Medistim ASA (OB:MEDI)

A Look At The Intrinsic Value Of Medistim ASA (OB:MEDI)

In this article we are going to estimate the intrinsic value of Medistim ASA ( OB:MEDI ) by estimating the company's...

Shareholder Returns

MEDINO Medical EquipmentNO Market
7D-14.0%5.8%-3.4%
1Y-9.4%-23.0%3.2%

Return vs Industry: MEDI exceeded the Norwegian Medical Equipment industry which returned -24.9% over the past year.

Return vs Market: MEDI underperformed the Norwegian Market which returned 3.4% over the past year.

Price Volatility

Is MEDI's price volatile compared to industry and market?
MEDI volatility
MEDI Average Weekly Movement8.6%
Medical Equipment Industry Average Movement6.8%
Market Average Movement7.2%
10% most volatile stocks in NO Market12.8%
10% least volatile stocks in NO Market3.9%

Stable Share Price: MEDI is not significantly more volatile than the rest of Norwegian stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: MEDI's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1984117Kari Krogstadhttps://www.medistim.com

Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis.

Medistim Fundamentals Summary

How do Medistim's earnings and revenue compare to its market cap?
MEDI fundamental statistics
Market Capkr4.63b
Earnings (TTM)kr92.80m
Revenue (TTM)kr431.32m

49.9x

P/E Ratio

10.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MEDI income statement (TTM)
Revenuekr431.32m
Cost of Revenuekr97.99m
Gross Profitkr333.32m
Other Expenseskr240.52m
Earningskr92.80m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 23, 2022

Earnings per share (EPS)5.09
Gross Margin77.28%
Net Profit Margin21.52%
Debt/Equity Ratio0%

How did MEDI perform over the long term?

See historical performance and comparison

Dividends

1.5%

Current Dividend Yield

74%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is MEDI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MEDI?

Other financial metrics that can be useful for relative valuation.

MEDI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue10.5x
Enterprise Value/EBITDA35.9x
PEG Ratio2.5x

Price to Earnings Ratio vs Peers

How does MEDI's PE Ratio compare to its peers?

MEDI PE Ratio vs Peers
The above table shows the PE ratio for MEDI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average46.6x

Price-To-Earnings vs Peers: MEDI is expensive based on its Price-To-Earnings Ratio (49.9x) compared to the peer average (46.6x).


Price to Earnings Ratio vs Industry

How does MEDI's PE Ratio compare vs other companies in the Medical Equipment Industry?

Price-To-Earnings vs Industry: MEDI is expensive based on its Price-To-Earnings Ratio (49.9x) compared to the European Medical Equipment industry average (27.3x)


Price to Earnings Ratio vs Fair Ratio

What is MEDI's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MEDI PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio49.9x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate MEDI's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of MEDI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MEDI (NOK254) is trading below our estimate of fair value (NOK268.32)

Significantly Below Fair Value: MEDI is trading below fair value, but not by a significant amount.


Price to Earnings Growth Ratio

PEG Ratio: MEDI is poor value based on its PEG Ratio (2.5x)


Discover undervalued companies

Future Growth

How is Medistim forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

4/6

Future Growth Score 4/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


20.0%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MEDI's forecast earnings growth (20% per year) is above the savings rate (1.1%).

Earnings vs Market: MEDI's earnings (20% per year) are forecast to grow faster than the Norwegian market (1.5% per year).

High Growth Earnings: MEDI's earnings are forecast to grow, but not significantly.

Revenue vs Market: MEDI's revenue (12.4% per year) is forecast to grow faster than the Norwegian market (0.2% per year).

High Growth Revenue: MEDI's revenue (12.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MEDI's Return on Equity is forecast to be high in 3 years time (28.1%)


Discover growth companies

Past Performance

How has Medistim performed over the past 5 years?

Past Performance Score

6/6

Past Performance Score 6/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


16.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MEDI has high quality earnings.

Growing Profit Margin: MEDI's current net profit margins (21.5%) are higher than last year (19.7%).


Past Earnings Growth Analysis

Earnings Trend: MEDI's earnings have grown by 16.3% per year over the past 5 years.

Accelerating Growth: MEDI's earnings growth over the past year (32.4%) exceeds its 5-year average (16.3% per year).

Earnings vs Industry: MEDI earnings growth over the past year (32.4%) exceeded the Medical Equipment industry 22.5%.


Return on Equity

High ROE: MEDI's Return on Equity (28.3%) is considered high.


Discover strong past performing companies

Financial Health

How is Medistim's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: MEDI's short term assets (NOK333.5M) exceed its short term liabilities (NOK81.2M).

Long Term Liabilities: MEDI's short term assets (NOK333.5M) exceed its long term liabilities (NOK18.6M).


Debt to Equity History and Analysis

Debt Level: MEDI is debt free.

Reducing Debt: MEDI has no debt compared to 5 years ago when its debt to equity ratio was 0.07%.

Debt Coverage: MEDI has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: MEDI has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Medistim current dividend yield, its reliability and sustainability?

Dividend Score

3/6

Dividend Score 3/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


1.48%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: MEDI's dividend (1.48%) isn’t notable compared to the bottom 25% of dividend payers in the Norwegian market (2.82%).

High Dividend: MEDI's dividend (1.48%) is low compared to the top 25% of dividend payers in the Norwegian market (7.24%).


Stability and Growth of Payments

Stable Dividend: MEDI's dividend payments have been volatile in the past 10 years.

Growing Dividend: MEDI's dividend payments have increased over the past 10 years.


Earnings Payout to Shareholders

Earnings Coverage: With its reasonable payout ratio (73.6%), MEDI's dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its reasonable cash payout ratio (56.5%), MEDI's dividend payments are covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

11.8yrs

Average management tenure


CEO

Kari Krogstad (57 yo)

12.75yrs

Tenure

kr6,395,468

Compensation

Ms. Kari Eian Krogstad serves as Director at Vistin Pharma ASA since June 24, a2020. She has been the Chief Executive Officer of Medistim ASA since September 1, 2009 and serves as its President. Ms. Krogst...


CEO Compensation Analysis

Compensation vs Market: Kari's total compensation ($USD648.07K) is about average for companies of similar size in the Norwegian market ($USD591.72K).

Compensation vs Earnings: Kari's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: MEDI's management team is seasoned and experienced (11.8 years average tenure).


Board Members

Experienced Board: MEDI's board of directors are considered experienced (8.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Medistim ASA's employee growth, exchange listings and data sources


Key Information

  • Name: Medistim ASA
  • Ticker: MEDI
  • Exchange: OB
  • Founded: 1984
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: kr4.633b
  • Shares outstanding: 18.24m
  • Website: https://www.medistim.com

Number of Employees


Location

  • Medistim ASA
  • Økernveien 94
  • Oslo
  • Oslo
  • 579
  • Norway

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/24 00:00
End of Day Share Price2022/06/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.